Semper Paratus shifts combined Tevogen Bio listing target to Nasdaq from NYSE American

Tevogen Bio Holdings Inc.

Parties agreed to seek Nasdaq listing for New Tevogen common stock and public warrants instead of NYSE American.
Prospectus Supplement filed on Jan 24, 2024 to revise prior proxy statement/prospectus.
Shareholder meeting to vote on business combination with Tevogen Bio remains scheduled for Jan 29, 2024.
Semper Paratus (LGST, LGSTW) will redomesticate to Delaware and rename to Tevogen Bio Holdings Inc. upon closing.
Tevogen Bio is a clinical-stage immunotherapy company with wholly owned IP including three granted patents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.